Pharma BD Deal Intelligence
Roche Holding AG / Zealand Pharma A/S
2025 · Co-Development · $5.3B · Complete
Announcement Sentiment
100
Strongly positive
Outcome Score
63
Largely worked — most objectives met.
Roche partnered with Zealand Pharma to co-develop petrelintide, an amylin analog for obesity, paying $1.65B upfront in a deal worth up to $5.3B.
Key facts
- Announced Mar 12, 2025
- Closed Jun 30, 2025
- Deal value $5.3B
- Deal type Co-Development
- Therapeutic area Metabolic
- Indications Obesity, Overweight
- Key assets petrelintide
- Mechanism Amylin receptor agonist
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals